These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 8786626)
1. [In vitro and in vivo antibacterial activities of sulopenem, a new penem antibiotic]. Komoto A; Otsuki M; Nishino T Jpn J Antibiot; 1996 Apr; 49(4):352-66. PubMed ID: 8786626 [TBL] [Abstract][Full Text] [Related]
2. [In vitro and in vivo activities of sulopenem compared with those of imipenem and cephalosporins]. Nagashima M; Goto S; Yoshida T; Matsunaga T; Shimohira H; Ogawa M Jpn J Antibiot; 1996 Apr; 49(4):303-23. PubMed ID: 8786623 [TBL] [Abstract][Full Text] [Related]
3. Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria. Zhanel GG; Pozdirca M; Golden AR; Lawrence CK; Zelenitsky S; Berry L; Schweizer F; Bay D; Adam H; Zhanel MA; Lagacé-Wiens P; Walkty A; Irfan N; Naber K; Lynch JP; Karlowsky JA Drugs; 2022 Apr; 82(5):533-557. PubMed ID: 35294769 [TBL] [Abstract][Full Text] [Related]
4. [In vitro antibacterial activity of a new parenteral penem, sulopenem]. Yoshida T; Tateda E; Hiramatsu K; Yokota T Jpn J Antibiot; 1996 Apr; 49(4):324-37. PubMed ID: 8786624 [TBL] [Abstract][Full Text] [Related]
5. [Antibacterial activity of sulopenem, a new parenteral penem antibiotic]. Inoue E; Komoto E; Taniyama Y; Mitsuhashi S Jpn J Antibiot; 1996 Apr; 49(4):338-51. PubMed ID: 8786625 [TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo antibacterial activities of meropenem, a new carbapenem antibiotic. Harabe E; Kawai Y; Kanazawa K; Otsuki M; Nishino T Drugs Exp Clin Res; 1992; 18(2):37-46. PubMed ID: 1644010 [TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo antibacterial activities of FK037, a new parenteral cephalosporin. Nishino T; Otsuki M; Hatano K; Nishihara Y Chemotherapy; 1994; 40(3):167-82. PubMed ID: 8205935 [TBL] [Abstract][Full Text] [Related]
8. [In vitro and in vivo antibacterial activities of pazufloxacin mesilate, a new injectable quinolone]. Nomura N; Mitsuyama J; Furuta Y; Yamada H; Nakata M; Fukuda T; Yamada H; Takahata M; Minami S Jpn J Antibiot; 2002 Aug; 55(4):412-39. PubMed ID: 12378871 [TBL] [Abstract][Full Text] [Related]
9. [In vitro activities of sulopenem, a new parenteral penem, against anaerobes]. Watanabe K; Kato N; Tanaka-Bandoh K; Tanaka Y; Kato H; Ueno K Jpn J Antibiot; 1996 Apr; 49(4):367-76. PubMed ID: 8786627 [TBL] [Abstract][Full Text] [Related]
10. In-vitro activity of meropenem imipenem, the penem HRE 664 and ceftazidine against clinical isolates from West Germany. Bauernfeind A; Jungwirth R; Schweighart S J Antimicrob Chemother; 1989 Sep; 24 Suppl A():73-84. PubMed ID: 2509418 [TBL] [Abstract][Full Text] [Related]
11. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2004). I. Susceptibility distribution]. Kumamoto Y; Tsukamoto T; Matsukawa M; Kunishima Y; Hirose T; Shigeta S; Yamaguti O; Ishibashi K; Suzutani T; Yoshida H; Imafuku Y; Murai M; Watanabe K; Kobayashi Y; Uchida H; Matsuda S; Sato S; Fujime M; Fujita K; Igari J; Oguri T; Yamaguchi K; Furuya N; Deguchi T; Ishihara S; Ooe H; Oka T; Kitamura M; Fukuhara Y; Kamidono S; Arakawa S; Kumon H; Monden K; Matsumoto T; Muratani T; Naito S; Egashira T; Konishi T; Kohno S; Hirakata Y; Kondo A; Matsuda J; Nakano M Jpn J Antibiot; 2006 Jun; 59(3):177-200. PubMed ID: 16913404 [TBL] [Abstract][Full Text] [Related]
12. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--II. Gram-negative bacteria]. Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T Jpn J Antibiot; 2003 Oct; 56(5):458-96. PubMed ID: 14692381 [TBL] [Abstract][Full Text] [Related]
13. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1994). I. Susceptibility distribution]. Kumamoto Y; Hirose T; Yokoo A; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Tazaki H; Iri H; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Kitagawa R; Igari J; Oguri T; Kosakai N; Yamaguchi K; Kashitani F; Yonezu S; Yamanaka Y; Takaha M; Iori F Jpn J Antibiot; 1996 May; 49(5):465-93. PubMed ID: 8752862 [TBL] [Abstract][Full Text] [Related]
14. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1995). I. Susceptibility distribution]. Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Hikichi Y; Shigeta S; Takanashi T; Shiraiwa Y; Ogiwara M; Yoshida H; Imafuku Y; Murai M; Watanabe K; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Igari J; Oguri T; Kosakai N; Yamaguchi K; Matsumoto T; Kashitani F; Tanaka M Jpn J Antibiot; 1997 Mar; 50(3):219-50. PubMed ID: 9575353 [TBL] [Abstract][Full Text] [Related]
15. Bactericidal activity of ertapenem against major intra-abdominal pathogens. Borbone S; Cascone C; Santagati M; Mezzatesta ML; Stefani S Int J Antimicrob Agents; 2006 Nov; 28(5):396-401. PubMed ID: 17045463 [TBL] [Abstract][Full Text] [Related]
16. Antimicrobial activity of imipenem against 1386 clinical isolates. Belobraydic KA; Qadri SM Methods Find Exp Clin Pharmacol; 1986 Nov; 8(11):675-8. PubMed ID: 3468319 [TBL] [Abstract][Full Text] [Related]
17. [Susceptibility of clinically isolated bacterial strains to imipenem/cilastatin sodium]. Daimon Y Jpn J Antibiot; 1990 Nov; 43(11):1948-55. PubMed ID: 2287059 [TBL] [Abstract][Full Text] [Related]
18. In vitro antibacterial activity and beta-lactamase stability of the new carbapenem SM-7338. Sumita Y; Inoue M; Mitsuhashi S Eur J Clin Microbiol Infect Dis; 1989 Oct; 8(10):908-16. PubMed ID: 2512140 [TBL] [Abstract][Full Text] [Related]